Where does Landos Biopharma, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Landos Biopharma, Inc. ranks #16,151 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Landos Biopharma, Inc. hold?

Landos Biopharma, Inc. holds 18 US utility patents granted between 2017 and 2023, spanning 8 technology areas.

What is Landos Biopharma, Inc.'s Innovation Score?

Landos Biopharma, Inc. has an Innovation Score of 40.4 out of 100 (top 36% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Landos Biopharma, Inc. focus on?

Landos Biopharma, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 18 patents, ranking #1,084 of 6,058 assignees active in that subclass. Grants appear in 8 CPC subclasses total.

Is Landos Biopharma, Inc.'s patent grant rate increasing or decreasing?

Landos Biopharma, Inc.'s recent grant velocity is +160% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Landos Biopharma, Inc.'s patents?

Landos Biopharma, Inc.'s patents average 25.4 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Landos Biopharma, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Landos Biopharma, Inc.

USPTO PatentsView assignee record - 18 granted patents across 8 technology areas, recorded in grant years 2017–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Landos ranks #16,151 of 49,997 tracked US assignees by granted-patent volume, with 18 patents across 8 technology areas.

#16,151
of 49,997 US assignees by volume: Top 36%
by Innovation Score (40.4/100): 25.4
avg claims per patent: +160%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R16151 · US Corporation #16,151 · 18 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 18 grants
MID-PACK #16,151/49,997
PHOTO-FINISH Kraton Chemical
CPC-NARROW A61P · 8 areas
INNOV-PAR 40.4/100
CLAIMS-DENSE 25.4 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +160% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Kraton Chemical LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Landos’s 40.4 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 10.2 pts (25%) Velocity 5.2 pts (13%) Breadth 10.0 pts (25%) Claim depth 15.0 pts (37%)

Qualcomm Incorporated · highest

85
Landos Biopharma · this assignee

40
3D Lighting… · lowest

7

What this shows Landos's Innovation Score is 40.4/100 (top 36% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Landos?

Each dot is one of Landos’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Landos’s own 25.4 claims/patent is ABOVE the 12.3 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Landos vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Landos's grants concentrate

Landos Biopharma, Inc. is a focused PatentsView assignee: 8 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2023 (4 grants) versus a trough of 1 in 2017. By volume, Landos sits between Kraton Chemical LLC and Leibniz-institut FÜR Plasmaforschung UND Technologie E.V..

Landos's three-year grant acceleration

Landos Biopharma, Inc. shows 7 grants in 2022–2024 against only 9 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Kraton Chemical

18
L-3 Communication…

18
L B Foster

18
L I F E

18
LAS Vegas Sands

18
Leavitt Medical

18
Legend3d

18
Leibniz-institut…

18
Landos Biopharma ◀

18

What this shows Landos holds 18 patents at rank #16,151, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Landos

By rank, the assignees closest to #16,151 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Landos's primary technology class.

Landos's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

40 Top 36% higher than 64% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2017–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table

Landos Biopharma, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2017	1	5.6%
2018	1	5.6%
2019	3	16.7%
2020	3	16.7%
2021	3	16.7%
2022	3	16.7%
2023	4	22.2%

Which technologies does Landos Biopharma, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 18

C07D - Heterocyclic Compounds 17

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 9

C07C - Acyclic OR Carbocyclic Compounds 8

Y02A - Technologies FOR Adaptation TO Climate Change 1

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 1

A01K - Animal HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; Rearing OR Breeding Animals, NOT Otherwise Provided FOR; NEW Breeds OF Animals 1

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 1

Top 8 of 8 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Landos Biopharma, Inc.'s patent record in context - here's where to go next.

Landos Biopharma, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #16,151 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Landos Biopharma, Inc. against Kraton Chemical LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 40.4/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.